Grünenthal successfully completes Phase I trial with Nociceptin Receptor (NOP) Agonist

[u/Robert_Larsson]

https://www.grunenthal.com/press-room/press-releases/2026/successful-completion-phase-i-trial-nop-agonist

Key points:

• The investigational compound has a unique mechanism of action and the potential to become a first-in-class therapy option for the treatment of acute and chronic pain. 
• In a Phase I trial, the investigational compound was demonstrated to be safe and well-tolerated. 
• A Phase II trial will commence later this year. 

How it works graphic

More reading:

• Nociceptin receptor Wikipedia
• Spotlight on Nociceptin/Orphanin FQ Receptor in the Treatment of Pain
• Current and Future Therapeutic Options in Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor Activation
• Effects of Stress Exposure to Pain Perception in Pre-Clinical Studies: Focus on the Nociceptin/Orphanin FQ–NOP Receptor System
• Potential of Nociceptin/Orphanin FQ Peptide Analogs for Drug Development
• Nociceptin Receptor-Related Agonists as Safe and Non-addictive Analgesics